People | December 22, 2023
Abbott India MD Vivek Kamath resigns
His resignation would be effective from March 18, 2024
His resignation would be effective from March 18, 2024
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
Currently, Venkat is Lead – Market Access, India at Pfizer
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Investment is additive to KKR’s existing health care growth strategy
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
The companies will work with investigators to share the results with the scientific community
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
